

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research; Contract Review Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act as amended (5 U.S.C., Appendix 2), announcement is made of an Agency for Health Care Policy and Research (AHCPR) Technical Review Committee (TRC) meeting. This TRC's charge is to provide review of contract proposals and recommendations to the Administrator, AHCPR, on the technical merit of proposals submitted in response to a Request for Proposals (RFPs) on "Technical, Analytical and Logistical Support Services for the Office of Research Review, Education and Policy". The RFP was published in the Commerce Business Daily on May 11, 1999.

The upcoming TRC meeting will be closed to the public in accordance with the Federal Advisory Committee Act (FACA), section 10(d) of 5 U.S.C., Appendix 2, implementing regulations, 41 CFR 101-6.1023, and procurement regulations, 48 CFR section 315.604(d). The discussions at this meeting of contract proposals submitted in response to the above-referenced RFP are likely to reveal proprietary and personal information concerning individuals associated with the proposals. Such information is exempt from disclosure under the above-cited FACA provision that protects the free exchange of candid views, and under the procurement rules that protects the contract proposal evaluation process.

Name of TRC: The Agency for Health Care Policy and Research—"Technical, Analytical and Logistical Support Services for the Office of Research Review, Education and Policy."

Date: August 19-20, 1999 (Closed to the public).

Place: Agency for Health Care Policy and Research, Conference Center, Conference Room B, 6010 Executive Boulevard, 4th Floor, Rockville, Maryland 20852.

Contact Person: Anyone wishing to obtain information regarding this meeting should contact Bonnie

Campbell, Office of Research Review, Education and Policy, Agency for Health Care Policy and Research, 2101 Executive Boulevard, Suite 400, Rockville, Maryland, 20852, 301-594-1846.

This notice is being published less than 15 days prior to the August 19-20 meeting due to the timing limitations imposed by the review and funding cycle.

Dated: August 3, 1999.

John M. Eisenberg,
Administrator.

[FR Doc. 99-20428 Filed 8-6-99; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO-99-25]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639-7090.

Comments are invited on (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Seleda

Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Projects

1. Antimalarial Drugs—New—The Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), is proposing a survey of pharmacy directors of inpatient health facilities to gain information about the availability of antimalarial medications in their pharmacies. In recent years, CDC has received increasing numbers of reports from health care providers and patients who have been unable to obtain, or experienced delays in obtaining, antimalarial drugs which were needed for patients in the United States who have been diagnosed with malaria. In the case of injectable quinidine gluconate, which is the treatment of choice for severe malaria, these delays in initiating appropriate therapy have been life threatening. The reasons for these shortages have varied from problems in drug supply and distribution from the manufacturer to decisions made by pharmacies to no longer stock the drugs. The American Society of Health System Pharmacists (ASHP) will provide CDC with a list of approximately 7,400 pharmacy directors of inpatient institutions in the U.S. Those listed will be surveyed through a mailed questionnaire. Participation in completing the proposed questionnaire will be voluntary. Information collected will include the pharmacy name and location, name of the pharmacy director, number of inpatient beds in the health facility, a list of antimalarial medications currently on formulary and in stock, the procedure and anticipated delay in obtaining injectable quinidine if needed and not currently in stock, and, if quinidine is no longer on formulary, the date it was taken off. Such information is essential for CDC to determine the potential need for and various options to improve the availability of critical antimalarial drugs in the United States. The total estimated cost to respondents is 0.

Form	Number of respondents	Number of responses per respondent	Average burden per respondent (in hrs.)	Response burden (total hrs. in study)
Questionnaire	7,400	1	0.16	1184